Catalent Inc. (NYSE:CTLT) traded at a new 52-week high today of $141.99. Approximately 296,000 shares have changed hands today, as compared to an average 30-day volume of 810,000 shares.
In the past 52 weeks, shares of Catalent Inc. have traded between a low of $79.65 and a high of $141.99 and is now at $141.60, which is 78% above that low price.
Catalent Inc is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent’s sales are generated in the United States, followed by Europe and the rest of the world. Most of the company’s sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. It operates in four operating segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
Based on a current price of $141.60, Catalent Inc. is currently 0.3% above its average consensus analyst price target of $141.19.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer